

**Notice of Amendment to the Karyopharm Therapeutics Inc.
Code of Ethics and Business Conduct**

On May 21, 2021, the Board of Directors of Karyopharm Therapeutics Inc. (the “Company”) approved an amended and restated Code of Ethics and Business Conduct (the “Code of Conduct”). The Code of Conduct applies to all directors, officers, and employees of the Company and its subsidiaries. The Code of Conduct was revised and updated to reflect current best practices, improve readability, enhance understanding of the Company’s standards of ethical business practices, and promote awareness of ethical issues that may be encountered in carrying out an employee’s or director’s responsibilities. The updated Code of Conduct does not materially change the responsibilities and obligations that previously applied to employees and directors.

The newly adopted Code of Conduct did not result in any explicit or implicit waiver of any provision of the Company’s prior Code of Conduct.